A pharmaceutical company specialising in turning magic mushrooms into a treatment for severe depression is expanding clinical trials after signing a deal with an NHS trust in the UK and King’s College London.
Compass Pathways hopes the new partnership will speed up work on this new and exciting treatment for depressive disorders, PTSD, anorexia and bipolar disorder. The company has raised $165 million to put into the partnership.
Mankind could do with some magic in treating the aforementioned illnesses more effectively than medicine has to date.
Phase 2 trials of their patented treatment are already underway.
